A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy

• Published in: Clinical cancer research Vol. 24; no. 15; pp. 3583 - 3592
• Main Authors: Song, Jiangdian, Shi, Jingyun, Dong, Di, Fang, Mengjie, Zhong, Wenzhao, Wang, Kun, Wu, Ning, Huang, Yanqi, Liu, Zhenyu, Cheng, Yue, Gan, Yuncui, Zhou, Yongzhao, Zhou, Ping, Chen, Bojiang, Liang, Changhong, Liu, Zaiyi, Li, Weimin, Tian, Jie
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research Inc 01.08.2018
• Subjects: Aged; Cancer; Carcinoma, Non-Small-Cell Lung - diagnostic imaging; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; Chemotherapy; Decision analysis; Design of experiments; Drug Resistance, Neoplasm - genetics; Epidermal growth factor receptors; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; Experimental design; Feature extraction; Female; Gefitinib - administration & dosage; Gefitinib - adverse effects; Humans; Lung cancer; Male; Middle Aged; Mutation; Neoplasm Staging; Non-small cell lung carcinoma; Patients; Positron Emission Tomography Computed Tomography; Prediction models; Progression-Free Survival; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein-tyrosine kinase; Regression analysis; Regression models; Statistical analysis; Survival; Tyrosine
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-17-2507

We established a CT-derived approach to achieve accurate progression-free survival (PFS) prediction to EGFR tyrosine kinase inhibitors (TKI) therapy in multicenter, stage IV -mutated non-small cell lung cancer (NSCLC) patients. A total of 1,032 CT-based phenotypic characteristics were extracted according to the intensity, shape, and texture of NSCLC pretherapy images. On the basis of these CT features extracted from 117 stage IV -mutant NSCLC patients, a CT-based phenotypic signature was proposed using a Cox regression model with LASSO penalty for the survival risk stratification of EGFR-TKI therapy. The signature was validated using two independent cohorts (101 and 96 patients, respectively). The benefit of EGFR-TKIs in stratified patients was then compared with another stage-IV -mutant NSCLC cohort only treated with standard chemotherapy (56 patients). Furthermore, an individualized prediction model incorporating the phenotypic signature and clinicopathologic risk characteristics was proposed for PFS prediction, and also validated by multicenter cohorts. The signature consisted of 12 CT features demonstrated good accuracy for discriminating patients with rapid and slow progression to EGFR-TKI therapy in three cohorts (HR: 3.61, 3.77, and 3.67, respectively). Rapid progression patients received EGFR TKIs did not show significant difference with patients underwent chemotherapy for progression-free survival benefit ( = 0.682). Decision curve analysis revealed that the proposed model significantly improved the clinical benefit compared with the clinicopathologic-based characteristics model ( < 0.0001). The proposed CT-based predictive strategy can achieve individualized prediction of PFS probability to EGFR-TKI therapy in NSCLCs, which holds promise of improving the pretherapy personalized management of TKIs. .